dexmedetomidine has been researched along with Neuroleptic Malignant Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajan, R; Sage, M | 1 |
| Hardman, MI; Sprung, J; Weingarten, TN | 1 |
1 review(s) available for dexmedetomidine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor Antagonists; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; Haloperidol; Humans; Lorazepam; Male; Melatonin; Neuroleptic Malignant Syndrome; Olanzapine; Receptors, GABA; Substance Withdrawal Syndrome; Substance-Related Disorders; Young Adult | 2019 |
1 other study(ies) available for dexmedetomidine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Successful Emergency Treatment of Refractory Neuroleptic Malignant Syndrome With Electroconvulsive Therapy and a Novel Use of Dexmedetomidine: A Case Report From California in the Era of COVID-19.
Topics: California; Combined Modality Therapy; COVID-19; Dexmedetomidine; Electroconvulsive Therapy; Female; Humans; Hypnotics and Sedatives; Middle Aged; Neuroleptic Malignant Syndrome; Pandemics; SARS-CoV-2 | 2021 |